Hoffmann-la Roche Inc.

Madrigal Pharmaceuticals, Inc.

Chromocell Corporation

F. Hoffmann-la Roche Ag

Stuart Hayden

Yimin Qian

Nancy-Ellen Haynes

David Robert Bolin

Jefferson Wright Tilley

Sung-Sau So

Fariborz Firooznia

Ramakanth Sarabu

Robert Francis Kester

Weiya Yun

Eric Mertz

Kevin Richard Guertin

Robert Zhiyong Luo

Adrian Wai-Hing Cheung

Kshitij Chhabilbhai Thakkar

Steven Joseph Berthel

Nathan Robert Scott

Lee Apostle McDermott

Lida Qi

Jenny Tan

Hao Zhou

John A Brinkman

Joseph Anthony Bilotta

Nicholas Marcopulos

Christine M Lukacs-Lesburg

Deshou Jiang

Purvi Shah

Kevin Curran

The present disclosure provides edible compositions comprising a flavor-grade sweet taste modulator or a combination of flavor-grade sweet taste modulators or a flavor-grade bitter taste blocker or a combination of flavor-grade bitter taste blockers of the present disclosure, food products comprising such edible compositions and methods of preparing such food products. The present disclosure also provides methods of reducing the amount of sugar in a food product, methods of reducing the caloric intake in a diet, and methods of enhancing sweet taste or blocking a bitter taste in a food product.

Compounds, compositions, and methods for modulating sweet taste

The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

Aminomethyl quinolone compounds

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Diacylglycerol acyltransferase inhibitors

Inhibitors of diacylglycerol acyltransferase

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Pyrrolidinone glucokinase activators

Growing community of inventors

Manalapan, NJ, United States of America

Stuart Hayden